Meeting Express . . . Navuliu mono-resistant: 240mg 30min is more convenient to administer!

The results of the checkmate 870 study confirmed the safety and reliability of the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients, mainly in Chinese population, with a fixed dose of 240 mg.]. The safety was good with the use of 240 mg fixed dose and 30 min infusion, which was consistent with previous critical studies based on body weight dose, and no new safety signal was found.] the safety characteristics of navulizumab in HBV infected and non HBV infected population were similar.] for the first time in Chinese patients, it has been confirmed that navulizumab has the same antitumor activity in the special population with EGFR mutation and HBV infection.30min infusion is safe and convenient. Checkmate 870 is an open label clinical study to evaluate the safety and efficacy of monotherapy with navulizumab in patients with advanced or metastatic NSCLC.recently, the results of the checkmate 870 study were released at the AACR II 2020 conference.the study was conducted with a fixed dose of 240 mg, 30 min intravenous infusion (once every two weeks) until the patient developed disease progression or intolerable conditions, up to 24 months.the results showed that the most common level 3-4 treatment-related selective adverse reactions were liver (2.3%), skin (1.6%), lung (1.0%) and endocrine (0.8%). The incidence of grade 5 treatment-related selective adverse reactions was 0%.in patients with HBV infection, the incidence of grade 3-5 treatment-related selective adverse reactions was 0%.in all patients, the total incidence of grade 3-4 treatment-related adverse reactions was 12.8%, and the withdrawal rate caused by grade 3-4 treatment-related adverse reactions was 2.0%.studies have shown that the safety characteristics of navulizumab in the treatment population are consistent with the previous key studies based on body weight dose (3mg / kg) and 60min infusion, and no new safety signals are found.subgroup analysis results in the intention to treat population, the researchers analyzed the EGFR mutation, HBV infection, histological type and PD-L1 expression.results showed that at a median follow-up of 9.6 months, the 6-month overall survival rate was 75% (95% CI: 70 – 79%) and the objective response rate (ORR) was 15.5%; the orr of HBV infected and non HBV infected patients was 17.6% and 15.4%, respectively, and the orr of EGFR gene mutation and non mutation patients were 14.7% and 14.2%, respectively.confirmed the anti-tumor activity of mAb navulieu in HBV infection and EGFR mutation population.researcher comments Professor Lu Shun, director of the oncology department of the affiliated Chest Hospital of Shanghai Jiaotong University, said: "as the first tumor immunotherapy drug approved for marketing in China, the safety of navulizumab has been widely confirmed in clinical practice at home and abroad.this study further confirmed that the fixed dose 30 min infusion regimen is equally safe in Chinese patients with advanced or metastatic NSCLC, including patients with EGFR mutation and HBV infection.this provides new evidence for improving the convenience of clinical use and applying it to special populations. More patients with advanced NSCLC will benefit from the treatment of navulizumab.”